The EA-PRO population (N = 216) comprised 71 patients with locally advanced/metastatic NTRK fusion-positive solid tumours and 145 patients with locally advanced/metastatic ROS1 fusion-positive NSCLC (Supplementary Figure S1, available at https://doi.org/10.1016/j.esmoop.2021.100113). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.